Recent Blog Posts

View Post: - News, Search Jobs, Events
27 Oct 2009
Lambert Eaton Myasthenic Syndrome (LEMS) is a rare autoimmune disease with the primary symptoms of muscle weakness. Muscle weakness in LEMS is caused by autoantibodies to voltage gated calcium channels leading to a reduction in the ...
View Blog: BioSpace.com Featured News and Stories - http://www.biospace.com/

---

View Post: Rodman & Renshaw : The Biotechnology Balance Sheet for the week of ...
2 Nov 2009 by leonardo  
Huxley is developing a proprietary form of 3,4-diaminopyridine (3,4-DAP), amifampridine phosphate, for the rare autoimmune disease Lambert Eaton Myasthenic Syndrome (LEMS). The acquisition comes a week after the Committee for Medicinal ...
View Blog: Zangani - Investor Community - http://www.zangani.com/

---

View Post: Lambert-Eaton myasthenic syndrome definition - Medical Dictionary ...
28 Aug 2008
Lambert-Eaton myasthenic syndrome: An autoimmune disease characterized by weakness and fatigue of the proximal muscles (those near the trunk), particularly the muscles of the pelvic girdle (the pelvis and hips) and the thighs, ...
View Blog: MedTerms Word of the Day - http://www.medterms.com/script/main/hp.asp

---

View Post: Autoimmune disorders of the neuromuscular junction Vincent A ...
21 Dec 2008 by Vincent Angela  
The Lambert Eaton myasthenic syndrome is another autoimmune form of NMJ disorder, but it is also a prototype paraneoplastic neurological syndrome as about 50% of the patients have small cell lung cancer. The distribution of muscle ...
View Blog: Table of Contents : Neurology India : 2009 - 57(4) - http://www.neurologyindia.com/currentissue.asp

---

View Post: BioMarin buys Huxley for orphan drug
27 Oct 2009
BioMarin Pharmaceutical has acquired Huxley Pharmaceuticals, a virtual biotech firm with only one product, a treatment for the rare autoimmune disease Lambert Eaton myasthenic syndrome (LEMS). It will pay $15 million up front plus ...
View Blog: Scrip News - Home - RSS - http://www.scripnews.com/home/

---

View Post: Open Label Trial Of 3,4-Diaminopyridine In Lambert-Eaton ...
30 Mar 2009
Purpose. The purpose of this study is to determine the effectiveness and adverse effects of 3,4-diaminopyridine for the treatment of the Lambert-Eaton Myasthenic Syndrome (LEMS). ...
View Blog: ClinicalTrials.gov: ALL - http://www.clinicaltrials.gov/ct2/results/rss.xml?rcv_s=03%2F21%2F2009&...

---

View Post: (BMRN) BioMarin Pharmaceutical Purchases Huxley Pharmaceuticals ...
27 Oct 2009 by vitalstocks  
... it has acquired the privately held Huxley Pharmaceuticals Inc., which possessed rights to a proprietary form of 3,4-diaminopyridine amifampridine phosphate ( 3,4-DAP), for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). ...
View Blog: Stock Blog Hub - http://www.stockbloghub.com/

---